BARDA is contributing funding for a Phase 3 clinical test of a Moderna messenger RNA vaccine that could protect against the strains of bird flu virus now spreading in U.S. dairy cows. The Moderna vaccine is currently in Phase 1/2 testing.
The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Panelists at MedCity INVEST Precision Medicine said startups can gain valuable expertise and experience through the process of seeking out non-dilutive funding.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine's progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!
The company had received $483 million from BARDA in April to fund the development of the vaccine, mRNA-1273, through Phase III, but that amount was based on a smaller anticipated number of participants than the 30,000 it now plans to enroll into the trial, named COVE.
The contract covers manufacture and supply of the two-antibody drug cocktail REGN-COV2. The company had announced Monday that it entered the drug into three late-stage clinical studies, both as a treatment for existing SARS-CoV-2 infections and a preventive treatment for healthy exposed people.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
The drugmaker licensed the vaccine last month from the University of Oxford, which is developing it in a Phase I/II clinical trial in southern England. The company also plans a Phase III study.
Rick Bright, who had been director of the Biomedical Advanced Research and Development Authority since 2016, is now filing a whistleblower complaint, saying he was placed in a more limited position at the NIH pushing back against promotion of hydroxychloroquine.
The funding will support the development of the vaccine, mRNA-1273, through to its potential licensing by the Food and Drug Administration. The company said a Phase II study is expected to start in the second quarter.
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Stem cell therapy is one way the government’s preparing for a nation impacted by nuclear disaster. Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield – a portion of the Bush-era […]
Release of smallpox as a bioterrorism weapon is a possibility that antiviral company Chimerix has been awarded $81 million to combat. The federal contract will be used to develop the Durham, North Carolina company's antiviral drug candidate into a smallpox treatment.